<p>WAVE Life Sciences Ltd. (NASDAQ:WVE - 获取免费报告) 从覆盖该公司的十四位分析师那里获得了 “适度买入” 的共识推荐，MarketBeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，十三位分析师给予该公司买入评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价格为 31.6667 美元。</p>
<p>获取 <strong>WAVE Life Sciences</strong> 警报：</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>几家研究公司对 WVE 发表了看法。瑞银集团在 12 月 16 日的研究报告中将 WAVE Life Sciences 的目标价格设定为 32.00 美元。摩根士丹利在 12 月 8 日的研究报告中将 WAVE Life Sciences 的目标价格设定为 28.00 美元。Wedbush 在 12 月 12 日的研究报告中将 WAVE Life Sciences 的目标价格从 20.00 美元上调至 33.00 美元，并给予该股票 “跑赢大盘” 的评级。Leerink Partners 在 12 月 8 日的报告中重新发布了 WAVE Life Sciences 的 “跑赢大盘” 评级。最后，B. Riley 在 12 月 12 日的研究报告中将 WAVE Life Sciences 的目标价格从 19.00 美元上调至 37.00 美元，并给予该股票 “买入” 评级。</p>
<p><strong>阅读我们最新的 WVE 股票报告</strong></p>
<h2>WAVE Life Sciences 的内部交易</h2>
<ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
<p>在其他 WAVE Life Sciences 的新闻中，董事 Adrian Rawcliffe 于 12 月 8 日出售了 42,000 股公司的股票。该股票以平均价格 15.00 美元出售，总交易额为 630,000.00 美元。交易完成后，该董事持有 12,700 股公司的股票，价值约 190,500 美元。此次交易使其持股减少了 76.78%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，主要股东 Plc Gsk 于 12 月 11 日购买了 1,470,000 股 WAVE Life Sciences 股票，交易总额为 27,930,000.00 美元，平均每股价格为 19.00 美元。交易完成后，该内部人士在公司中持有 18,245,691 股，价值 346,668,129 美元。这代表其持股增加了 8.76%。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 902,742 股公司股票，价值 13,313,763 美元。公司内部人士持有公司 23.98% 的股份。</p>
<h2>对 WAVE Life Sciences 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近对 WVE 的持仓进行了调整。Adage Capital Partners GP L.L.C. 在第二季度将其在 WAVE Life Sciences 的持仓增加了 20.0%。Adage Capital Partners GP L.L.C. 现在拥有 15,016,500 股公司股票，价值 97,607,000 美元，在上个季度又购买了 2,500,000 股。683 Capital Management LLC 在第二季度将其在 WAVE Life Sciences 的持仓增加了 4.5%。683 Capital Management LLC 现在拥有 4,100,000 股公司股票，价值 26,650,000 美元，在此期间又收购了 175,000 股。Federated Hermes Inc. 在第三季度将其在 WAVE Life Sciences 的持仓增加了 678,144.7%。Federated Hermes Inc. 现在拥有 3,750,693 股公司股票，价值 27,455,000 美元，在上个季度又收购了 3,750,140 股。Loomis Sayles &amp; Co. L P 在第二季度将其在 WAVE Life Sciences 的持仓增加了 35.3%。Loomis Sayles &amp; Co. L P 现在拥有 3,295,700 股公司股票，价值 21,422,000 美元，在上个季度又收购了 859,160 股。最后，Emerald Advisers LLC 在第二季度将其在 WAVE Life Sciences 的持仓增加了 3.9%。Emerald Advisers LLC 现在拥有 3,257,119 股公司股票，价值 21,171,000 美元，在此期间又购买了 123,561 股。机构投资者持有公司 89.73% 的股份。</p>
<h2>WAVE Life Sciences 的价格表现</h2>
<ul>
<li>Sarepta Therapeutics Inc.：为什么它是一个崛起的基因治疗明星</li>
</ul>
<p>NASDAQ WVE 的股票在周五开盘价为 17.77 美元。该股票的市值为 29.7 亿美元，市盈率为-23.69，贝塔值为-1.72。该公司有 50 日移动平均线为 10.52 美元，200 日移动平均线为 8.77 美元。WAVE Life Sciences 的 52 周低点为 5.28 美元，52 周高点为 21.73 美元。</p>
<p>WAVE Life Sciences (NASDAQ:WVE - 获取免费报告) 最近于 11 月 10 日公布了季度财报。该公司报告每股收益（EPS）为-0.32 美元，低于分析师的共识预期（-0.30 美元）0.02 美元。WAVE Life Sciences 的股本回报率为-75.61%，净利润率为-111.64%。该公司本季度的收入为 761 万美元，而共识预期为 985 万美元。平均而言，卖方分析师预计 WAVE Life Sciences 本年度将发布-1.14 的每股收益。</p>
<h2>WAVE Life Sciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发立体纯度寡核苷酸疗法，旨在解决具有高度未满足医疗需求的严重疾病。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
<p>该公司的研发管线包括针对神经肌肉疾病（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期心血管和肝脏相关的指征。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 WAVE 生命科学更好的股票</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>特朗普 5000 亿美元计划推动这些每月分红</li>
<li>[紧急！] SpaceX 即将上市！– IPO 前的动态</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>正式开火…</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 WAVE 生命科学吗？</h2>
<p>在你考虑 WAVE 生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前…而 WAVE 生命科学并不在名单上。</p>
<p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

WAVE生命科学

<p>WAVE 生命科学有限公司（NASDAQ:WVE）获得了十四位分析师的共识评级为 “适度买入”，其中一位评级为卖出，十三位评级为买入。平均十二个月的目标价格为 31.67 美元。最近的内部交易包括一位主要股东购买了 147 万股，以及一位董事出售了 42,000 股。机构投资者持有该公司 89.73% 的股份。该股票在周五以 17.77 美元开盘，市值为 29.7 亿美元</p>

<p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $31.6667.</p>
<div class="lb-trans"><p>WAVE Life Sciences Ltd. (NASDAQ:WVE - 获取免费报告) 从覆盖该公司的十四位分析师那里获得了 “适度买入” 的共识推荐，MarketBeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，十三位分析师给予该公司买入评级。在过去一年中，覆盖该股票的经纪人给出的平均十二个月目标价格为 31.6667 美元。</p>
</div><p>Get <strong>WAVE Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>WAVE Life Sciences</strong> 警报：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Several research firms have weighed in on WVE. UBS Group set a $32.00 price objective on WAVE Life Sciences in a research report on Tuesday, December 16th. Morgan Stanley set a $28.00 price target on shares of WAVE Life Sciences in a research note on Monday, December 8th. Wedbush lifted their price objective on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, December 12th. Leerink Partners reissued an &#34;outperform&#34; rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Finally, B. Riley increased their target price on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, December 12th.</p>
<div class="lb-trans"><p>几家研究公司对 WVE 发表了看法。瑞银集团在 12 月 16 日的研究报告中将 WAVE Life Sciences 的目标价格设定为 32.00 美元。摩根士丹利在 12 月 8 日的研究报告中将 WAVE Life Sciences 的目标价格设定为 28.00 美元。Wedbush 在 12 月 12 日的研究报告中将 WAVE Life Sciences 的目标价格从 20.00 美元上调至 33.00 美元，并给予该股票 “跑赢大盘” 的评级。Leerink Partners 在 12 月 8 日的报告中重新发布了 WAVE Life Sciences 的 “跑赢大盘” 评级。最后，B. Riley 在 12 月 12 日的研究报告中将 WAVE Life Sciences 的目标价格从 19.00 美元上调至 37.00 美元，并给予该股票 “买入” 评级。</p>
</div><p><strong>Read Our Latest Stock Report on WVE</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 WVE 股票报告</strong></p>
</div><h2>Insider Transactions at WAVE Life Sciences</h2>
<div class="lb-trans"><h2>WAVE Life Sciences 的内部交易</h2>
</div><ul>
<li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li>
</ul>
<div class="lb-trans"><ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
</div><p>In other WAVE Life Sciences news, Director Adrian Rawcliffe sold 42,000 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.00, for a total transaction of $630,000.00. Following the completion of the transaction, the director owned 12,700 shares of the company's stock, valued at approximately $190,500. The trade was a 76.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Plc Gsk purchased 1,470,000 shares of WAVE Life Sciences stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the purchase, the insider owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 902,742 shares of company stock valued at $13,313,763. Company insiders own 23.98% of the company's stock.</p>
<div class="lb-trans"><p>在其他 WAVE Life Sciences 的新闻中，董事 Adrian Rawcliffe 于 12 月 8 日出售了 42,000 股公司的股票。该股票以平均价格 15.00 美元出售，总交易额为 630,000.00 美元。交易完成后，该董事持有 12,700 股公司的股票，价值约 190,500 美元。此次交易使其持股减少了 76.78%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，主要股东 Plc Gsk 于 12 月 11 日购买了 1,470,000 股 WAVE Life Sciences 股票，交易总额为 27,930,000.00 美元，平均每股价格为 19.00 美元。交易完成后，该内部人士在公司中持有 18,245,691 股，价值 346,668,129 美元。这代表其持股增加了 8.76%。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 902,742 股公司股票，价值 13,313,763 美元。公司内部人士持有公司 23.98% 的股份。</p>
</div><h2>Hedge Funds Weigh In On WAVE Life Sciences</h2>
<div class="lb-trans"><h2>对 WAVE Life Sciences 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in WVE. Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after buying an additional 2,500,000 shares in the last quarter. 683 Capital Management LLC grew its stake in WAVE Life Sciences by 4.5% in the second quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company's stock valued at $26,650,000 after acquiring an additional 175,000 shares during the period. Federated Hermes Inc. increased its holdings in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company's stock valued at $27,455,000 after acquiring an additional 3,750,140 shares in the last quarter. Loomis Sayles &amp; Co. L P increased its holdings in shares of WAVE Life Sciences by 35.3% during the second quarter. Loomis Sayles &amp; Co. L P now owns 3,295,700 shares of the company's stock valued at $21,422,000 after acquiring an additional 859,160 shares in the last quarter. Finally, Emerald Advisers LLC raised its position in shares of WAVE Life Sciences by 3.9% during the second quarter. Emerald Advisers LLC now owns 3,257,119 shares of the company's stock worth $21,171,000 after purchasing an additional 123,561 shares during the period. Institutional investors own 89.73% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 WVE 的持仓进行了调整。Adage Capital Partners GP L.L.C. 在第二季度将其在 WAVE Life Sciences 的持仓增加了 20.0%。Adage Capital Partners GP L.L.C. 现在拥有 15,016,500 股公司股票，价值 97,607,000 美元，在上个季度又购买了 2,500,000 股。683 Capital Management LLC 在第二季度将其在 WAVE Life Sciences 的持仓增加了 4.5%。683 Capital Management LLC 现在拥有 4,100,000 股公司股票，价值 26,650,000 美元，在此期间又收购了 175,000 股。Federated Hermes Inc. 在第三季度将其在 WAVE Life Sciences 的持仓增加了 678,144.7%。Federated Hermes Inc. 现在拥有 3,750,693 股公司股票，价值 27,455,000 美元，在上个季度又收购了 3,750,140 股。Loomis Sayles &amp; Co. L P 在第二季度将其在 WAVE Life Sciences 的持仓增加了 35.3%。Loomis Sayles &amp; Co. L P 现在拥有 3,295,700 股公司股票，价值 21,422,000 美元，在上个季度又收购了 859,160 股。最后，Emerald Advisers LLC 在第二季度将其在 WAVE Life Sciences 的持仓增加了 3.9%。Emerald Advisers LLC 现在拥有 3,257,119 股公司股票，价值 21,171,000 美元，在此期间又购买了 123,561 股。机构投资者持有公司 89.73% 的股份。</p>
</div><h2>WAVE Life Sciences Price Performance</h2>
<div class="lb-trans"><h2>WAVE Life Sciences 的价格表现</h2>
</div><ul>
<li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta Therapeutics Inc.：为什么它是一个崛起的基因治疗明星</li>
</ul>
</div><p>Shares of NASDAQ WVE opened at $17.77 on Friday. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -23.69 and a beta of -1.72. The business has a 50-day moving average of $10.52 and a 200-day moving average of $8.77. WAVE Life Sciences has a fifty-two week low of $5.28 and a fifty-two week high of $21.73.</p>
<div class="lb-trans"><p>NASDAQ WVE 的股票在周五开盘价为 17.77 美元。该股票的市值为 29.7 亿美元，市盈率为-23.69，贝塔值为-1.72。该公司有 50 日移动平均线为 10.52 美元，200 日移动平均线为 8.77 美元。WAVE Life Sciences 的 52 周低点为 5.28 美元，52 周高点为 21.73 美元。</p>
</div><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The company had revenue of $7.61 million for the quarter, compared to the consensus estimate of $9.85 million. On average, sell-side analysts expect that WAVE Life Sciences will post -1.14 EPS for the current year.</p>
<div class="lb-trans"><p>WAVE Life Sciences (NASDAQ:WVE - 获取免费报告) 最近于 11 月 10 日公布了季度财报。该公司报告每股收益（EPS）为-0.32 美元，低于分析师的共识预期（-0.30 美元）0.02 美元。WAVE Life Sciences 的股本回报率为-75.61%，净利润率为-111.64%。该公司本季度的收入为 761 万美元，而共识预期为 985 万美元。平均而言，卖方分析师预计 WAVE Life Sciences 本年度将发布-1.14 的每股收益。</p>
</div><h2>WAVE Life Sciences Company Profile</h2>
<div class="lb-trans"><h2>WAVE Life Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.</p>
<div class="lb-trans"><p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发立体纯度寡核苷酸疗法，旨在解决具有高度未满足医疗需求的严重疾病。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
</div><p>The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.</p>
<div class="lb-trans"><p>该公司的研发管线包括针对神经肌肉疾病（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期心血管和肝脏相关的指征。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than WAVE Life Sciences</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Trump's $500B plan is fueling these monthly dividends</li>
<li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Shots officially fired…</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 WAVE 生命科学更好的股票</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>特朗普 5000 亿美元计划推动这些每月分红</li>
<li>[紧急！] SpaceX 即将上市！– IPO 前的动态</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>正式开火…</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=WVE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 WAVE 生命科学吗？</h2>
</div><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 WAVE 生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前…而 WAVE 生命科学并不在名单上。</p>
</div><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师给予 WAVE 生命科学有限公司（NASDAQ:WVE）“适度买入” 的一致评级